Skip to main content

Advertisement

SpringerLink
Log in

Usefulness of albumin–globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Albumin–globulin ratio (AGR), which is calculated by dividing serum albumin by serum globulin, is considered as a cancer-related inflammation biomarker. Although the prognosis of many solid cancers has been shown to be associated with AGR, there are no studies to demonstrate the association between the prognosis of thyroid cancer and AGR. The purpose of this study is to reveal the relationship between AGR and overall survival (OS) in patients with thyroid cancer who received radioactive iodine therapy (RIT).

Methods

Eighty-eight patients with thyroid cancer who had received RIT for the first time in our institution were included. The values before RIT were adopted as initial measurements for serum albumin, globulin, and thyroglobulin (Tg) and used for analysis. Patients were divided into two groups based on the AGR value. We analyzed the relationship between clinical factors and treatment outcome.

Results

The median follow-up period was 92.4 months (range: 30.1–173.9 months). The 5-year OS and progression-free survival (PFS) were 94% and 54%, respectively. Seventeen patients (< 65 years, 8; and ≥ 65 years, 9) died during the follow-up period. Low AGR was significantly associated with OS in both univariate and multivariate analyses (p = 0.0059 and p = 0.0120, respectively). As the 5-year OS was as high as 94%, there was no significant difference in survival rate between the two groups during the first 5 years. However, there seemed to be a remarkable difference in 10 years after the first RIT. On the other hand, Tg was significantly associated with PFS in both univariate and multivariate analyses (p = 0.0016 and p = 0.0441, respectively). In patients under the age of 65, the PFS rate was significantly lower in the low AGR group (p < 0.0001), while there was no difference in PFS rate between the two AGR groups in patients aged 65 years or older.

Conclusions

AGR may be used as a prognostic factor in relatively younger patients with thyroid cancer treated with radioiodine, while it may be less useful in the older. Overall, it may be an independent prognostic factor for long-term survival in those with thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Vecchia CL, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95.

    Article  Google Scholar 

  2. Song H-J, Qiu Z-L, Shen C-T, Wei W-J, Luo Q-Y. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. 2015;173:399–408.

    Article  CAS  Google Scholar 

  3. Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884–9.

    Article  Google Scholar 

  4. Wang R, Zhang Y, Tan J, Zhang G, Zhang R, Zheng W, et al. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study. Medicine (Baltimore). 2017. https://doi.org/10.1097/MD.0000000000006809.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bandeira L, Padovani RDP, Ticly AL, Cury AN, Scalissi NM, Marone MMS, et al. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer. Arch Endocrinol Metab. 2017;61:590–9.

    Article  Google Scholar 

  6. Choi YM, Kim WG, Kwon H, Jeon MJ, Lee JJ, Ryu J-S, et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2016;175:165–72.

    Article  CAS  Google Scholar 

  7. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121–7.

    CAS  PubMed  Google Scholar 

  8. Görges R, Maniecki M, Jentzen W, Sheu SN-Y, Mann K, Bockisch A, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol. 2005;153:49–55.

    Article  Google Scholar 

  9. He J, Pan H, Liang W, Xiao D, Chen X, Guo M, et al. Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis. J Cancer. 2017;8:4002–10.

    Article  Google Scholar 

  10. Königsbrügge O, Posch F, Riedl J, Reitter E-M, Zielinski C, Pabinger I, et al. Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist. 2016;21:252–7.

    Article  Google Scholar 

  11. Shimizu T, Ishizuka M, Shibuya N, Tanaka G, Abe A, Aoki T, et al. Preoperative globulin-to-albumin ratio predicts outcome after curative resection in patients with gastric cancer. Ann Gastroenterol Surg. 2018;2:367–75.

    Article  Google Scholar 

  12. Hachiya H, Ishizuka M, Takagi K, Iwasaki Y, Shibuya N, Nishi Y, et al. Clinical significance of the globulin-to-albumin ratio for prediction of postoperative survival in patients with colorectal cancer. Ann Gastroenterol Surg. 2018;2:434–41.

    Article  Google Scholar 

  13. Xu Y, Xu X, Xi C, Ye N, Wang Y. Prognostic value of preoperative albumin to globulin ratio in elderly patients with rectal cancer. Medicine (Baltimore). 2019. https://doi.org/10.1097/MD0000000000016066.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Duran AO, Inanc M, Karaca H, Dogan I, Berk V, Bozkurt O, et al. Albumin-globulin ratio for prediction of long-term mortality in lung adenocarcinoma patients. Asian Pac J Cancer Prev. 2014;15:6449–53.

    Article  Google Scholar 

  15. Deng Y, Pang Q, Miao R-C, Chen W, Zhou Y-Y, Bi J-B, et al. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Oncol Targets Ther. 2016;9:5317–28.

    Article  CAS  Google Scholar 

  16. Koparal MY, Polat F, Cetin S, Bulut EC, Sözen TS. Prognostic role of preoperative albumin to globulin ratio in predicting survival of clear cell renal cell carcinoma. Int Braz J Urol. 2018;44:933–46.

    Article  Google Scholar 

  17. Hussain A, Almenfi HF, Almehdewi AM, Hamza MS, Bhat MS, Vijayashankar NP. Laboratory features of newly diagnosed multiple myeloma patients. Cureus. 2019. https://doi.org/10.7759/cureus.4716.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mander SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.

    Article  Google Scholar 

  19. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014;384:319–28.

    Article  CAS  Google Scholar 

  20. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 8th ed. Hoboken: Wiley; 2017.

    Google Scholar 

  21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  Google Scholar 

  22. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    Article  CAS  Google Scholar 

  23. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.

    Article  CAS  Google Scholar 

  24. Gomi I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K, et al. Relationship between serum albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci Vitaminol. 2007;53:37–42.

    Article  CAS  Google Scholar 

  25. Wu C-Y, Hu H-Y, Huang N, Chou Y-C, Li C-P, Chou Y-J. Albumin levels and cause-specific mortality in community-dwelling older adults. Prev Med. 2018;112:145–51.

    Article  Google Scholar 

  26. Salive ME, Cornoni-Huntley J, Phillips CL, Guralnik JM, Cohen HJ, Ostfeld AM, et al. Serum albumin in older persons: relationship with age and health status. J Clin Epidemiol. 1992;45:213–21.

    Article  CAS  Google Scholar 

  27. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010. https://doi.org/10.1186/1475-2891-9-69.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zhong Z, Sanchez-Lopez KM. Autophagy, inflammation and immunity: a troika governing cancer and its treatment. Cell. 2016;166:288–98.

    Article  CAS  Google Scholar 

  29. Hu D, Zheng H, Liu H, Li M, Ren W, Liao W, et al. Immunoglobulin expression and its biological significance in cancer cells. Cell Mol Immunol. 2008;5:319–24.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Ehime University Hospital, Shitsukawa, Toon, Ehime, Japan

    Noriko Takata, Masao Miyagawa, Takuya Matsuda, Masahiro Takakado, Tomohisa Okada, Naoto Kawaguchi, Kenji Makita, Hirofumi Ishikawa, Shintaro Tsuruoka, Kotaro Uwatsu & Teruhito Kido

Authors
  1. Noriko Takata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masao Miyagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuya Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiro Takakado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomohisa Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoto Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenji Makita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirofumi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shintaro Tsuruoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kotaro Uwatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Teruhito Kido
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noriko Takata.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takata, N., Miyagawa, M., Matsuda, T. et al. Usefulness of albumin–globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine. Ann Nucl Med 35, 1015–1021 (2021). https://doi.org/10.1007/s12149-021-01635-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-021-01635-2

Keywords

Search

Navigation